Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report), Entrada Therapeutics Inc (TRDA – Research Report) and Minerva Neurosciences (NERV – Research Report).
Vertex Pharmaceuticals (VRTX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Vertex Pharmaceuticals, with a price target of $380.00. The company’s shares closed last Tuesday at $347.74.
According to TipRanks.com, Fein is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vertex Pharmaceuticals with a $381.57 average price target, representing an 8.6% upside. In a report issued on July 21, Bank of America Securities also maintained a Buy rating on the stock with a $400.00 price target.
See today’s best-performing stocks on TipRanks >>
Entrada Therapeutics Inc (TRDA)
In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Entrada Therapeutics Inc, with a price target of $25.00. The company’s shares closed last Tuesday at $16.94.
According to TipRanks.com, Pachaiyappan is a 3-star analyst with an average return of
Entrada Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
Minerva Neurosciences (NERV)
H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Minerva Neurosciences today and set a price target of $11.00. The company’s shares closed last Tuesday at $10.38.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
Currently, the analyst consensus on Minerva Neurosciences is a Hold with an average price target of $11.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRTX:
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex Pharmaceuticals price target raised to $400 from $350 at BofA
- Vertex Pharmaceuticals granted approval for label extension of Orkambi
- Vertex Pharmaceuticals price target raised to $340 from $305 at Morgan Stanley
- Sigilon Therapeutics downgraded to Neutral from Buy at BTIG
